Lexicon Pharmaceuticals (LXRX) Interest Expenses (2010 - 2023)

Lexicon Pharmaceuticals (LXRX) has 14 years of Interest Expenses data on file, last reported at $3.9 million in Q3 2023.

• Interest Expenses for Q3 2023 came in at $3.9 million, up 351.27% year-over-year; the trailing twelve-month figure through Jun 2024 was $3.9 million (down 32.17% YoY), and the FY2022 annual result was $2.8 million, up 246.63% from the prior year.
• Interest Expenses climbed to $3.9 million in Q3 2023 per LXRX's latest filing, from $2.0 million in the prior quarter.
• Over five years, Interest Expenses peaked at $5.2 million in Q3 2019 and troughed at $110000.0 in Q1 2022.
• A 5-year average of $2.4 million and a median of $1.8 million in 2023 frame the typical range for Interest Expenses.
• The sharpest annual moves came in 2021 and 2023: Interest Expenses plunged 96.75% in 2021, then jumped 1555.45% in 2023.
• A 5-year view of Interest Expenses shows it stood at $5.2 million in 2019, then slumped by 96.73% to $170000.0 in 2020, then surged by 73.53% to $295000.0 in 2021, then jumped by 273.9% to $1.1 million in 2022, then surged by 253.49% to $3.9 million in 2023.
• Business Quant data shows LXRX's Interest Expenses at $3.9 million in Q3 2023, $2.0 million in Q2 2023, and $1.8 million in Q1 2023.